Innate Pharma Stock Net Income
| IPHA Stock | USD 1.78 0.04 2.30% |
As of the 23rd of January, Innate Pharma retains the Market Risk Adjusted Performance of (0.38), standard deviation of 4.84, and Risk Adjusted Performance of (0.02). Innate Pharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Innate Pharma Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 17.6485 | Revenue | Earnings Share (0.64) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -44.5 M | -42.3 M | |
| Net Loss | -44.5 M | -46.8 M | |
| Net Loss | -52.3 M | -49.7 M | |
| Net Loss | (0.93) | (0.89) | |
| Net Income Per E B T | 1.00 | 0.95 |
Innate | Net Income | Build AI portfolio with Innate Stock |
Latest Innate Pharma's Net Income Growth Pattern
Below is the plot of the Net Income of Innate Pharma over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Innate Pharma financial statement analysis. It represents the amount of money remaining after all of Innate Pharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Innate Pharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Innate Pharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (49.47 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Innate Net Income Regression Statistics
| Arithmetic Mean | (24,574,506) | |
| Coefficient Of Variation | (100.43) | |
| Mean Deviation | 22,064,948 | |
| Median | (19,647,000) | |
| Standard Deviation | 24,679,723 | |
| Sample Variance | 609.1T | |
| Range | 76.6M | |
| R-Value | (0.64) | |
| Mean Square Error | 385.8T | |
| R-Squared | 0.41 | |
| Significance | 0.01 | |
| Slope | (3,115,034) | |
| Total Sum of Squares | 9745.4T |
Innate Net Income History
Other Fundumenentals of Innate Pharma
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Innate Pharma Net Income component correlations
Innate Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Innate Pharma is extremely important. It helps to project a fair market value of Innate Stock properly, considering its historical fundamentals such as Net Income. Since Innate Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Innate Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Innate Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.75) | Earnings Share (0.64) | Revenue Per Share | Quarterly Revenue Growth (0.61) | Return On Assets |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Innate Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Innate Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Innate Pharma.
| 10/25/2025 |
| 01/23/2026 |
If you would invest 0.00 in Innate Pharma on October 25, 2025 and sell it all today you would earn a total of 0.00 from holding Innate Pharma or generate 0.0% return on investment in Innate Pharma over 90 days. Innate Pharma is related to or competes with Cardiff Oncology, Rani Therapeutics, Milestone Pharmaceuticals, Compugen, Corbus Pharmaceuticals, Molecular Partners, and Nuvectis Pharma. Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the trea... More
Innate Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Innate Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Innate Pharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 39.49 | |||
| Value At Risk | (5.21) | |||
| Potential Upside | 4.02 |
Innate Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Innate Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Innate Pharma's standard deviation. In reality, there are many statistical measures that can use Innate Pharma historical prices to predict the future Innate Pharma's volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.24) | |||
| Total Risk Alpha | (0.81) | |||
| Treynor Ratio | (0.39) |
Innate Pharma January 23, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.38) | |||
| Mean Deviation | 2.66 | |||
| Coefficient Of Variation | (2,699) | |||
| Standard Deviation | 4.84 | |||
| Variance | 23.43 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.24) | |||
| Total Risk Alpha | (0.81) | |||
| Treynor Ratio | (0.39) | |||
| Maximum Drawdown | 39.49 | |||
| Value At Risk | (5.21) | |||
| Potential Upside | 4.02 | |||
| Skewness | 3.21 | |||
| Kurtosis | 21.07 |
Innate Pharma Backtested Returns
Innate Pharma holds Efficiency (Sharpe) Ratio of -0.0761, which attests that the entity had a -0.0761 % return per unit of risk over the last 3 months. Innate Pharma exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Innate Pharma's Standard Deviation of 4.84, market risk adjusted performance of (0.38), and Risk Adjusted Performance of (0.02) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 0.49, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Innate Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Innate Pharma is expected to be smaller as well. At this point, Innate Pharma has a negative expected return of -0.37%. Please make sure to check out Innate Pharma's skewness, and the relationship between the treynor ratio and daily balance of power , to decide if Innate Pharma performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.38 |
Below average predictability
Innate Pharma has below average predictability. Overlapping area represents the amount of predictability between Innate Pharma time series from 25th of October 2025 to 9th of December 2025 and 9th of December 2025 to 23rd of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Innate Pharma price movement. The serial correlation of 0.38 indicates that just about 38.0% of current Innate Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.38 | |
| Spearman Rank Test | 0.44 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Innate Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Innate Pharma reported net income of (49.47 Million). This is 114.5% lower than that of the Biotechnology sector and 170.63% lower than that of the Health Care industry. The net income for all United States stocks is 108.66% higher than that of the company.
Innate Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Innate Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Innate Pharma could also be used in its relative valuation, which is a method of valuing Innate Pharma by comparing valuation metrics of similar companies.Innate Pharma is currently under evaluation in net income category among its peers.
Innate Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Innate Pharma from analyzing Innate Pharma's financial statements. These drivers represent accounts that assess Innate Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Innate Pharma's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 271.0M | 200.4M | 159.6M | 117.6M | 135.2M | 128.5M | |
| Enterprise Value | 211.5M | 158.5M | 128.9M | 82.6M | 94.9M | 90.2M |
Innate Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in Innate Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Innate Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Innate Pharma's value.| Shares | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 51.2 K | Steward Partners Investment Advisory, Llc | 2025-03-31 | 0.0 | Citadel Advisors Llc | 2025-06-30 | 26.6 K | Millennium Management Llc | 2025-06-30 | 11.7 K | Ubs Group Ag | 2025-06-30 | 6 K | Gamma Investing Llc | 2025-06-30 | 3.5 K | Rhumbline Advisers | 2025-06-30 | 470 | Barclays Plc | 2025-06-30 | 307 | Optiver Holding B.v. | 2025-06-30 | 101 | Principal Securities Inc | 2025-06-30 | 45.0 | Tower Research Capital Llc | 2025-06-30 | 0.0 |
Innate Fundamentals
| Return On Equity | -2.71 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (5.23) % | ||||
| Current Valuation | 124.16 M | ||||
| Shares Outstanding | 93.71 M | ||||
| Shares Owned By Institutions | 0.15 % | ||||
| Number Of Shares Shorted | 242.46 K | ||||
| Price To Book | 28.12 X | ||||
| Price To Sales | 13.20 X | ||||
| Revenue | 12.62 M | ||||
| Gross Profit | (30.79 M) | ||||
| EBITDA | (46.91 M) | ||||
| Net Income | (49.47 M) | ||||
| Cash And Equivalents | 123.35 M | ||||
| Cash Per Share | 1.54 X | ||||
| Total Debt | 31 M | ||||
| Debt To Equity | 0.37 % | ||||
| Current Ratio | 2.34 X | ||||
| Book Value Per Share | 0.07 X | ||||
| Cash Flow From Operations | (6.9 M) | ||||
| Short Ratio | 8.92 X | ||||
| Earnings Per Share | (0.64) X | ||||
| Target Price | 5.75 | ||||
| Number Of Employees | 174 | ||||
| Beta | 0.59 | ||||
| Market Capitalization | 166.8 M | ||||
| Total Asset | 111.06 M | ||||
| Retained Earnings | (386.36 M) | ||||
| Working Capital | 52.76 M | ||||
| Net Asset | 111.06 M |
About Innate Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Innate Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Innate Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Innate Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:Check out Innate Pharma Piotroski F Score and Innate Pharma Altman Z Score analysis. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.75) | Earnings Share (0.64) | Revenue Per Share | Quarterly Revenue Growth (0.61) | Return On Assets |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.